Reduction of beta cell mass: partial insulin secretory compensation from the residual beta cell population in the nicotinamide?streptozotocin G�ttingen minipig after oral glucose in vivo and in the perfused pancreas

Abstract

Aims/hypothesis. A progressive loss of beta cell function and mass are important contributory factors in the development and progression of type 2 diabetes. The aim of this study was to evaluate the effects of a primary reduction in beta cell mass on beta cell function in vivo and in the perfused pancreas and to relate these characteristics to beta cell mass. Methods. The beta cell mass of six Göttingen minipigs was reduced chemically (using 67 mg/kg nicotinamide and 125 mg/kg streptozotocin). Six untreated minipigs were kept as control animals. Insulin responses were evaluated in vivo using the mixed meal tolerance test (2 g/kg oral glucose) and in the isolated perfused pancreata from the same animals by stimulation with glucose, glucagon-like peptide-1 or arginine. Results. Beta cell mass was reduced in the beta-cellreduced animals compared with the control minipigs (182±76 vs 464±156 mg, p<0.01). AUC glucose was increased in the beta-cell-reduced animals (1383±385 vs 853±113 mmol·l −1 ·min in control minipigs, p<0.01), as was the insulin response to oral glucose per unit of beta cell mass (123±84 vs 56±24 pmol·l -1 ·min·mg -1 , p<0.05). Total in vitro insulin secretion was increased per unit of beta cell mass in nicotinamide + streptozotocin pancreata compared to controls (83.7±45.9 vs 34.6±14.4 nmol/mg beta cells, p<0.05) with responses to glucose and glucagon-like peptide-1 showing a partial compensation for reduced beta cell mass, whereas no compensation was seen in response to arginine. Conclusions/interpretation. A primary reduction in beta cell mass impairs glucose tolerance and leads to a compensatory increase in insulin secretion from the remaining beta cells after oral glucose in vivo, which is even more apparent in the perfused pancreas. It remains to be determined whether this compensation can be maintained in the long term.

β-cell Related Amyloidosis Localized to the Islets of Langerhans, Type II Diabetes Mellitus and Liponecrotic Pancreatitis in Rheumatoid Arthritis: A Postmortem Clinicopathologic Statistical Study of 234 Autopsy Patients

“…Recent studies confirm the reduced number and abnormal function of β-cells [57][58][59] accompanied with increased insulin secretion by the remaining β-cells [58]. In our patients the number of a-, b-, g-, and d-cells decreased in proportion to the amount of deposited IAPP, and the number of apoptotic cells increased.…”

Attenuated Wnt Signaling Perturbs Pancreatic Growth but Not Pancreatic Function

“…Rats infused with glucose or lipids were shown to achieve maintenance of normoglycemia by dramatically increasing their insulin secretory response paralleled by enhanced ␤-cell proliferation 1-2 days after infusion, leading to subsequent increase in ␤-cell mass (46). Finally, chemical reduction of ␤-cell mass in minipigs, which provokes glucose intolerance, resulted in an increased insulin response from the residual ␤-cell population during a mixed-meal tolerance test (47). Our data suggest that the Ipf1/Frz8CRD mice also display compensatory ␤-cell adaptations, and thus these mice could provide a useful tool for unraveling the cellular and molecular mechanisms underlying such ␤-cell compensatory adaptations.…”

The Short- and Long-Term Effect of Liraglutide on the Beta Cell Function in Type 2 Diabetic Patients

“…It is known that early phase insulin secretion is reduced in pancreatic β cells of diabetic patients. The decrease in the amount of pancreatic β cells, which may have been one reason for reduction of early phase insulin secretion [9] [10], seemed to diminish the simulative effect of the GLP-1 receptor agonist on insulin's responsiveness to glucose. In our study, duration of diabetes (13.1 [SD 8.4] years) was about fourtimes compared to a previous report [6].…”